Stockreport

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Immuneering Corporation - Class A  (IMRX) 
PDF - Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financin [Read more]